Company-initiated clinical trials in Denmark in 2013

Based on a survey among members of DANSK BIOTEK (Danish Association of Biotechnology Industries and Lif (Danish Association of the Pharmaceutical Industry).

Trend in the number of trials for Lif companies

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

Stagnation in the number of company-initiated clinical trials in Denmark

DANSK BIOTEK and Lif's members carried out a total of 296 clinical trials in 2013 – 99 of which were new trials.

The stabilisation noted in 2012 thus continued into 2013.

Trials conducted under the aegis of CROs

73 trials were conducted under the aegis of external CROs* in 2013.

After a marked increase between 2011 and 2012 (50 to 82), numbers of this type of trial have now again dropped back slightly.

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013*Contract Research Organisations

In 2013, a total of 16,249 individuals participated in clinical trials in Denmark.

This was significantly down on the previous three years when the number of trial subjects was more stable.

The drop was also due to an increase in the proportion of early stage trials in which not so many subjects usually participate.

Early stage trials are increasing, especially for cancer.

Drop in numbers of trial subjects

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

Trend in numbers of trial subjects

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

* * *

* This year’s counting does not include patients participating in clinical trials

taking place under the auspices of external CROs.

Number of personnel engaged in clinical research

1,854 full-time internal company personnel were engaged in clinical research in 2013, slightly up on previous years.

198 of these were engaged in clinical research carried out in Denmark. This was down on the 225 reported in 2012.

A further 55 full-time personnel were engaged in clinical research in Denmark via external CROs. This was in line with 2012.

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

1,854 personnel.

Expenditure on clinical trials

External expenditure by members of DANSK BIOTEK and Lif were in total DKK 212.4m in 2013 for research primarily done by the national health service.

This was markedly down on 2012. The stability noted since 2010 has now been replaced by a decline.

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

Distribution of expenditure on clinical research in 2013

External spending on clinical trials managed and conducted by Lif and DANSK BIOTEK’s member companies totalled DKK 157.6m.

Added to this external expenditure via CROs on fees and contributions to hospitals/university institutions, research foundations, investigators, lab reports, etc., totalled DKK 21.9m.

DKK 32.9m was spent on investigator-initiated trials.

Total external spending amounted to DKK 212.4m

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

Clinical studies on children: General increase since 2009

Number of non-intervention trials is stable

Source: Lif and DANSK BIOTEK’s survey ofclinical research activities in Denmark in 2013

Find all the reports at Lif.dk

The Infographic can be downloaded from lif.dk (only in Danish)